Home » Stocks » KZIA

Kazia Therapeutics Limited (KZIA)

Stock Price: $10.28 USD -0.21 (-2.00%)
Updated Jan 25, 2021 1:56 PM EST - Market open
Market Cap 84.00M
Revenue (ttm) 731,724
Net Income (ttm) -8.60M
Shares Out 62.17M
EPS (ttm) -0.92
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day January 25
Last Price $10.28
Previous Close $10.49
Change ($) -0.21
Change (%) -2.00%
Day's Open 10.76
Day's Range 10.20 - 10.74
Day's Volume 100,601
52-Week Range 2.56 - 13.47

News

InvestorPlace - 5 months ago

Kazia Therapeutics (KZIA) news for Friday includes a designation from the U.S. Food and Drug Administration sending KZIA stock flying high.

About KZIA

Kazia Therapeutics Limited, an oncology-focused biotechnology company, develops anti-cancer drugs. Its lead development candidate is GDC-0084, a small molecule, brain-penetrant inhibitor of the PI3K/Akt/mTor pathway, which is developed as a potential therapy for glioblastoma. The company is also developing Cantrixil, which is being developed for the treatment of ovarian cancer and is in hospitals across Australia and the United States under an Investigational New Drug application. Kazia Therapeutics Limited has collaboration agreements with St ... [Read more...]

Industry
Biotechnology
IPO Date
Jan 6, 1999
CEO
Dr. James Garner M.A.I.C.D., M.B.A., B.Sc., M.A., MBA, MBBS, B.Sc (
Stock Exchange
NASDAQ
Ticker Symbol
KZIA
Full Company Profile

Financial Performance

In 2020, KZIA's revenue was 1.06 million, a decrease of -32.20% compared to the previous year's 1.57 million. Losses were -12.47 million, 21.4% more than in 2019.

Financial numbers in millions AUD.
Financial Statements

Analyst Forecasts

According to one analyst, the rating for KZIA stock is "Buy" and the 12-month stock price forecast is 17.03.

Price Target
$17.03
Analyst Consensus: Buy